Armodafinil vs NSI-189

Mechanism

The isolated R-enantiomer of racemic modafinil, sharing the same primary mechanism — selective inhibition of the dopamine transporter (DAT) — but with distinct pharmacokinetics. The R-enantiomer has a terminal half-life of ~15 hours vs. ~4-5 hours for the S-enantiomer, resulting in 33-40% higher plasma AUC compared to equimolar racemic modafinil. This translates to more sustained wakefulness-promoting activity throughout the day. Same downstream activation of orexinergic, histaminergic, and noradrenergic pathways as modafinil.

Standard Dosing

75-150 mg once daily (for educational context only — prescription medication in most jurisdictions)

Timing

Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours.

Cycle Duration

Same as modafinil; not typically cycled in clinical use.

Side Effects

• Headache
• Nausea
• Dizziness
• Insomnia (more pronounced than modafinil due to longer half-life)
• Anxiety
• Dry mouth
• Diarrhea
• Stevens-Johnson syndrome (very rare)

Contraindications

• Same as modafinil: mitral valve prolapse, left ventricular hypertrophy, severe hepatic impairment, severe anxiety/psychotic disorders, hypersensitivity, pregnancy

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners